Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head ...

If resolved, and if benefit is expected to outweigh risk, resume treatment with close monitoring ALYFTREK and TRIKAFTA should not be used in patients with severe hepatic impairment. ALYFTREK and ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Vertex also presented the results of a post hoc analysis from the Phase 3 randomized, controlled and open-label trials of ALYFTREK (abstract WS19.04) which suggest treatment with ALYFTREK is ...

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Oral presentation on outcomes following ...

Non-congenital lens opacities/cataracts have been reported in pediatric patients treated with TRIKAFTA, which contain ivacaftor (similar to an active ingredient in ALYFTREK). Baseline and follow-up ...